Aberrant DNA Methylation of SOCS1 Gene is Not Associated with Resistance to Imatinib Mesylate among Chronic Myeloid Leukemia Patients

Author(s): Marjanu Hikmah Elias, Husin Azlan, Abdul Aziz Baba, Ravindran Ankathil*.

Journal Name: Cardiovascular & Hematological Disorders-Drug Targets
(Formerly Current Drug Targets - Cardiovascular & Hematological Disorders)

Volume 18 , Issue 3 , 2018

Become EABM
Become Reviewer

Graphical Abstract:


Background: In exploring the cause of Imatinib Mesylate (IM) resistance among Chronic Myeloid Leukemia (CML) patients who do not harbor BCR-ABL dependent mechanism, BCR-ABL independent pathways are the most probable pathways that should be explored. In BCR-ABL independent pathway, SOCS1 plays an important role as it helps in regulating optimal JAK/STAT activity.

Objective: To identify the association of SOCS1 gene hypermethylation in mediating IM Resistance.

Method: The SOCS1 promoter methylation level of 92 BCR-ABL non mutated IM resistant CML patients, 83 IM good response CML patients and 5 normal samples from healthy individuals were measured using Methylation Specific-High Resolution Melt (MS-HRM) analysis.

Results: Both primers used to amplify promoter region from -333 to -223 and from -332 to -188 showed less than 10% methylation in all CML and normal samples. Consequently, there was no significant difference in SOCS1 promoter methylation level between IM resistant and IM good response patients.

Conclusion: SOCS1 promoter methylation level is not suitable to be used as one of the biomarkers for predicting the possibility of acquiring resistance among CML patients treated with IM.

Keywords: Chronic myeloid leukemia, imatinib mesylate, methylation, high resolution melt analysis, cytokine signaling tumour.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Page: [234 - 238]
Pages: 5
DOI: 10.2174/1871529X18666180419101416
Price: $65

Article Metrics

PDF: 23